Molecular Partners AG Sponsored ADR (NASDAQ:MOLN) Sees Significant Increase in Short Interest

Molecular Partners AG Sponsored ADR (NASDAQ:MOLN) was the recipient of a large growth in short interest in the month of October. As of October 15th, there was short interest totaling 580 shares, a growth of 134.8% from the September 30th total of 247 shares. Currently, 0.0% of the shares of the company are short sold. Based on an average daily trading volume, of 1,840 shares, the days-to-cover ratio is presently 0.3 days.

Analyst Upgrades and Downgrades

A number of analysts recently commented on MOLN shares. HC Wainwright reiterated a “buy” rating on shares of Molecular Partners in a research report on Monday, July 6th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Molecular Partners in a research note on Friday, October 2nd. Two investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Molecular Partners presently has a consensus rating of “Hold” and a consensus target price of $8.38.

Molecular Partners Trading Up 2.5%

Molecular Partners stock traded up $0.09 during trading on Friday, reaching $3.62. The company had a trading volume of 1,753 shares, compared to its average volume of 2,200. The firm has a market capitalization of $146.16 million, a price-to-earnings ratio of -2.15 and a beta of 1.11. The firm’s 50-day simple moving average is $4.03 and its 200 day simple moving average is $4.18. Molecular Partners has a 52 week low of $3.51 and a 52 week high of $5.36.

Molecular Partners (NASDAQ:MOLN) last released its quarterly earnings results on Thursday, October 29th. The company reported ($0.38) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.46) by $0.08. On average, analysts predict that Molecular Partners will post -1.28 earnings per share for the current year.

About Molecular Partners

Molecular Partners AG is a clinical-stage biotechnology company headquartered in Schlieren, Switzerland. The company develops therapeutic molecules based on its proprietary DARPin platform, which uses designed ankyrin repeat proteins to create targeted, multi-specific medicines intended to address complex disease pathways.

Molecular Partners’ research and development activities have focused primarily on oncology, ophthalmology and infectious diseases. Its pipeline has included experimental programs designed to engage multiple biological targets, with the goal of improving treatment effectiveness and addressing limitations associated with conventional antibody-based therapies.